CanSino Biologics Headquarters

Headquarters: 401-420, 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District, Tianjin, PRC, China

Website : www.cansinotech.com

Hong Kong: Room 1901, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay Hong Kong

Telephone：022-58213600

Fax：022-58213677

E-mail: info@cansinotech.com

Ad5-EBOV Consult：022-58213613

Ad5-EBOV E-mail : ebov@cansinotech.com

CanSino Biologics Inc. (CanSinoBIO, stock 6185.HK) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide. 

Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with now more than 450 employees, one approved vaccine for Ebola virus disease (Ad5-EBOV) and 16 vaccine candidates in the product pipeline. CanSinoBIO has been successfully listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) since March 2019. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates.

Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed four key platform technologies, including adenovirus-based viral vector vaccine, conjugation, protein structure design and recombination as well as vaccine formulation technologies. 

In addition, the company has in-licensed a number of new technologies and intellectual properties through collaborations with international research organizations and biotechnology companies. CanSinoBIO collaborates through partnerships with world-class academic centers or start-up companies that develop innovative technologies, to prepare the portfolio of the next decades and ensure sustainable growth of the company.